Michael Ross

Michael Ross has a wealth of experience in translational and biomarker research. Michael began their professional career in 2010 as a Summer Research Intern at Washington University School of Medicine in St. Louis, where they studied the interaction between morphine use and extreme itch symptoms. In 2012, they returned to the same institution as a Doctoral Researcher in the Lab of Dr. Katherine Weilbaecher, where they focused on identifying and targeting a site-specific cancer marker for drug delivery. In 2017, they worked as a Clinical Protocol Manager at Where4Care. From 2018 to 2020, they worked at FogPharma as a Scientist I: Translational Biology, where they established primary human T cell immunological assays and led the development of protocols to screen and evaluate cell-penetrating miniproteins. Michael then joined Unum Therapeutics as a Scientist I: Translational Medicine / Biomarker Development, where they designed and executed a T cell infiltration biomarker assessment of clinical tumor biopsies. In 2020, they moved to TCR2 Therapeutics Inc. as a Principal Scientist: Translational Sciences and Senior Scientist: Translational Sciences. Currently, they are employed at Immunitas Therapeutics as a Principal Scientist: Translational and Biomarker Research.

Michael Ross obtained a Bachelor of Science (B.S.) in Biology with a Biochemistry Concentration from Haverford College in 2012. Michael then went on to pursue a Doctor of Philosophy - PhD in Molecular Cell Biology at Washington University School of Medicine in St. Louis, which they completed in 2018. In 2017, they obtained a National Institutes of Health (NIH) Clinical and Translational Course Certification, as well as an Association of Clinical Research Professionals (ACRP): Good Clinical Practice (GCP) certification from Washington University School of Medicine - Research Education & Information program. Finally, in 2018, they obtained a Regulatory Affairs Certificate: Pharmaceuticals from the Regulatory Affairs Professionals Society (RAPS).